Key result
Interferon-alfa for advanced renal cell carcinoma yielded a median overall survival of 13 months, with median survival of 30, 14, and 5 months for favorable, intermediate, and poor risk groups.
Why the study?
What are the outcome data and prognostic criteria for patients with metastatic renal cell carcinoma treated with interferon-alfa as initial systemic therapy?
Cohort (n=463)
What are the outcome data and prognostic criteria for patients with metastatic renal cell carcinoma treated with interferon-alfa as initial systemic therapy?
A prognostic model based on five clinical features can stratify survival risk in patients with advanced RCC treated with interferon-alfa, providing a baseline for future clinical trials.
No takes yet. Share an insight, caveat, or question.
Provides historical survival benchmarks by risk group for interferon-alfa in metastatic RCC; leaves open applicability to modern therapies.
Motzer et al. (2002) conducted a cohort in metastatic renal cell carcinoma (RCC) (n=463). interferon-alfa was evaluated on overall survival and time to progression. Interferon-alfa for advanced renal cell carcinoma yielded a median overall survival of 13 months, with median survival of 30, 14, and 5 months for favorable, intermediate, and poor risk groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: